The recent approval of Aduhelm™, an amyloid beta-directed antibody has led to players seeking approval for similar therapies; various interventions are being evaluated for the treatment / management of the inherently complex neurodegenerative disease Roots Analysis has announced the addition of “Alzheimer’s Disease Market (2nd Edition), 2021-2031” report to its list of offerings. […]
The Alzheimer’s disease market – Roots Analysis Read More »
The recent approval of Aduhelm™, an amyloid beta-directed antibody has led to players seeking approval for similar therapies; various interventions are being evaluated for the treatment / management of the inherently complex neurodegenerative disease Roots Analysis has announced the addition of “Alzheimer’s Disease Market (2nd Edition), 2021-2031” report to its list of offerings.
Roots Analysis has announced the addition of “Alzheimer’s Disease Market (2nd Edition), 2021-2031” report to its list of offerings. Limited treatment options and unmet needs are the key drivers of research activity in this domain. Several industry and non-industry players are presently engaged in developing various types of disease modifying interventions and drug /
